It’s beginning to look a lot like M&A season; Aduhelm runs into more resistance; Eli Lilly, Bristol Myers get in early on cancer efforts; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
As JP Morgan moves #JPM22 fully virtual, so will Endpoints News. We’re taking our multi-day hybrid event schedule online, with no live cocktail hour or networking events but plenty of timely news, insightful panels and fireside chats previewing the new year. We’ll be sad to not see our friends and colleagues on site, but we encourage everyone to still register for the event and join the conversation.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,700+ biopharma pros reading Endpoints daily — and it's free.